Associate, Department of Medicine (Gastroenterology & Liver Diseases)
Cell therapy to replace diseased liver cells, to provide genetically-deficient functions, and to supplement hepatic functions is of significant interest. The utilization of primary human hepatocytes for biomedical research, drug development, and treatment of liver diseases is hindered by the limited availability of donated livers and the variability of their derived hepatocytes. A critical need for these applications concerns harnessing stem cells such as pluriopotent stem cells to generate suitable liver cells. Simultaneously, this will be helpful for obtaining novel research tools and in drug development, toxicology studies, and cell therapy. Studying characterization and identification of stem progenitor cells of liver will provide insights of origin of progenitor cells and their role in tissue repair and for cell replacement therapies in regenerative medicine. Developing drug-induced liver failure animal models for evaluation of cell therapy potential of stem cell derived cells. Studying methods to demonstrate vascularization of transplanted tissues/cells using biomaterial scaffolds for applications in tissue engineering and regenerative medicine. Developing organoid liver tissue in vitro culture system for applications in disease modeling and drug development.
More Information About Dr. Sriram Bandi
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Golding Building, Room 101
Bronx, NY 10461